We have developed a TheraVac regimen consisting of two arms: one arm consisting of i.t. administration of R848 and HMGN1 which promoted the activation and homing of tDCs; the other arm consisting of a inhibitor (e.g. low dose of CY, anti-CTLA4 or anti-PD-L1) which countered the immunosuppression in the tumor tissues and tumor-bearing hosts. The gene discussed is CD274; the disease is neoplasm.